Scimega Launches New Reverse Feasibility Resource Center to Attract the Best Oncology Compounds for Canadian Cancer Patients - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Scimega Launches New Reverse Feasibility Resource Center to Attract the Best Oncology Compounds for Canadian Cancer Patients

Source: Company News Release

Scimega Research, (www.scimega.com) the experts in clinical oncology, is pleased to announce the launch of its newReverse Feasibility Resource Centre, a unique initiative that complements its highly successful Reverse Feasibility Program that matches the patient recruitment needs of U.S. oncology sponsors with the scientific interests of Canadian investigators and the treatment needs of their patients.

This microsite will enhance sponsor access to the program by providing regular updates that highlight Canada’s expertise in both early and late phase oncology trials. It currently features important information such as the number of oncology sites, key investigators, and catchment area size for each of the ten Canadian provinces.

Sponsors can sign up to receive free quarterly updates on the types of trials Scimega’s Reverse Feasibility Champions are looking to participate in. The Oncology Trial Needs Report for Canada will highlight the number of sites actively looking for trials, based on lines of treatment, tumor types and targets. 

“The Reverse Feasibility Program was launched in 2009 to attract state-of-the-art clinical research to Canada,” said Denise Deakin, President & co-founder of Scimega Research. “It was founded on the premise that long-standing relationships between Scimega and top performing oncology sites could be leveraged by sponsors to maximize the performance and quality of their trials, while enhancing the overall clinical trial experience for both investigators and patients,” continued Ms. Deakin.

“Using this approach, we’ve seen as much as a 50% reduction is study start-up times, while meeting targeted patient recruitment objectives. It’s really proven to be win-win situation as sponsors are thrilled with the performance metrics, while clinicians and their patients are happy to take participate in well designed, cutting-edge trials. We’re hoping the new Resource Centre will help facilitate many more of these positive experiences.”

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
88%
Borrow lightly from EMA's pathway program?
4%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Company News Release,
Click here